Chantix Tablet, Film Coated
Product Images NDC 43353-899

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Chantix (NDC 43353-899). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 1 mg (43353 899 05)

Packaging label for CHANTIX 1 mg film-coated tablets, containing 4200 tablets. The label identifies the active ingredient as varenicline tartrate and states the product is for oral use only. It includes storage instructions between 20-25 degrees Celsius and is repackaged by Aphena Pharma Solutions - Tennessee, LLC. The original manufacturer is Pfizer Ireland Pharmaceuticals, Dublin, Ireland. The product is prescription only.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Chemical Structure (Chantix 01)

Chemical structure diagram of the active ingredient varenicline tartrate, showing molecular components with aromatic rings and functional groups including carboxyl and hydroxyl groups.*

FDA Label Image

Figure 1 (Chantix 02)

A bar chart comparing different treatment groups across five studies. The vertical axis represents percentages from 0% to 60%, while the horizontal axis shows treatment groups and study numbers. Treatments include CHANTIX 0.5 mg BID, CHANTIX 1.0 mg BID, CHANTIX flexible, Bupropion SR 150 mg BID, and Placebo, with data bars displaying mean percentages and error bars for variability.*

FDA Label Image

Figure 2 (Chantix 03)

A bar chart comparing the percentage values of CHANTIX 0.5 mg BID, CHANTIX 1.0 mg BID, flexible dosing, and placebo across four different studies labeled Study 2, Study 3, Study 4, and Study 5. Additional comparisons in Studies 4 and 5 include Bupropion SR 150 mg BID. Each study section shows vertical bars with error bars representing variability.*

FDA Label Image

Figure 3 (Chantix 04)

A line graph comparing the percentage of continuous abstinent subjects over 52 weeks of nontreatment follow-up. Two groups are shown: CHANTIX 1.0 mg BID and placebo. The x-axis represents follow-up duration in weeks; the y-axis shows percent continuous abstinent. The CHANTIX group maintains higher abstinence rates than placebo throughout the period.*

FDA Label Image

Logo (Chantix 05)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.